Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients
Open Access
- 13 April 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (15) , 2143-2147
Abstract
Key Points: HIV-associated MCD remains a relapsing remitting disease despite rituximab-based therapy. Most patients can be salvaged at relapse by retreating with rituximab, but the risk of developing HHV8-associated lymphomas remains.Keywords
This publication has 22 references indexed in Scilit:
- Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman diseaseBlood, 2014
- Diagnostic Criteria Schemes for Multicentric Castleman Disease in 75 CasesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman diseaseCurrent Opinion in Oncology, 2012
- Clinical Features and Outcome in HIV-Associated Multicentric Castleman's DiseaseJournal of Clinical Oncology, 2011
- CD20 expression in the HHV‐8‐infected lymphoid cells in multicentric Castleman diseaseHistopathology, 2009
- The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s diseaseAnnals of Oncology, 2009
- Brief Communication: Rituximab in HIV-Associated Multicentric Castleman DiseaseAnnals of Internal Medicine, 2007
- Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB TrialJournal of Clinical Oncology, 2007
- Kaposi sarcoma-associated herpesvirus infects monotypic (IgMlambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disordersBlood, 2001
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977